Role of dopamine D1 receptor in 3-fluoromethamphetamine-induced neurotoxicity in mice

Nguyen, Phuong Tram; Shin, Eun Joo; Dang, Duy Khanh; Tran, Hai Quyen; Jang, Choon‐Gon; Jeong, Ji Hoon; Lee, Yu Jeung; Hj, Lee; Lee, Yong Sup; Yamada, Kiyofumi; Nabeshima, Toshitaka; Kim, Hyoung Chun

doi:10.1016/j.neuint.2017.11.017

Cited by 11 publications

(6 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with these findings, our results demonstrate that acute administration of 3‐FMA at a dose of 0.5 mg/kg and 1.0 mg/kg significantly increased locomotor activity. Based on the previous study that 3‐FMA acts on dopaminergic system, 14 it can be speculated that 3‐FMA produces psychobehavioral properties via activation of the dopaminergic system in the brain. In general, intermittent or repeated exposure to drugs results in progressively greater locomotor activation to the drug over time, a phenomenon known as behavioral sensitization 55 .…”

Section: Discussionmentioning

confidence: 99%

“…Among these behavioral methods, locomotor activity is one of the most well-known tests to evaluate behavioral changes after exposure to psychostimulants. 16,54,55 Drug-induced increase in psychomotor activity is closely related to [11][12][13][14]. Left y-axis, drug infusion; right y-axis, final ratio completed to access saline, 3-FMA, and METH.…”

Section: Primed Reinstatement Of 3-fma Reinforcementmentioning

confidence: 99%

“…However, scientific evidence for the psychopharmacological effects of 3‐FMA has not been sufficiently characterized. To date, only one study has reported that a single and high dose of 3‐FMA administration causes behavioral impairments and dopaminergic neuronal deficits in the striatum of mice 14 …”

Section: Introductionmentioning

confidence: 99%

“…To date, only one study has reported that a single and high dose of 3-FMA administration causes behavioral impairments and dopaminergic neuronal deficits in the striatum of mice. 14 In animal models, the locomotor activity test, conditioned place preference (CPP) procedure, and intravenous (i.v.) drug self-administration paradigms have been widely used to assess and predict the abuse potential of various drugs.…”

mentioning

confidence: 99%

See 3 more Smart Citations

The potent psychomotor, rewarding and reinforcing properties of 3‐fluoromethamphetamine in rodents

et al. 2019

Self Cite

View full text Add to dashboard Cite

3-fluoromethamphetamine (3-FMA), a derivative of methamphetamine (METH), produces behavioral impairment and deficits in dopaminergic transmission in the striatum of mice. The abuse potential of 3-FMA has not been fully characterized. The aim of this study was to evaluate the effects of 3-FMA on locomotor activity as well as its rewarding and reinforcing properties in the conditioned place preference (CPP) and self-administration procedures. Intravenous (i.v.) administration of 3-FMA (0.5 and 1.0 mg/kg) significantly increased locomotor activity in a dose-dependent manner in rats. In the CPP procedure, intraperitoneal administration of 3-FMA (10 and 30 mg/kg) produced a significant alteration in place preference in mice. In the selfadministration paradigms, 3-FMA showed drug-taking behavior at the dose of 0.1 mg/kg/infusion (i.v.) during 2 hr sessions under fixed ratio schedules and high breakpoints at the dose of 0.3 and 1.0 mg/kg/infusion (i.v.) during 6 hr sessions under progressive ratio schedule of reinforcement in rats. A priming injection of 3-FMA (0.4 mg/kg, i.v.), METH (0.2 mg/kg, i.v.), or cocaine (2.0 mg/kg, i.v.) reinstated 3-FMAseeking behavior after an extinction period in 3-FMA-trained rats during 2 hr session. Taken together, these findings demonstrate robust psychomotor, rewarding and reinforcing properties of 3-FMA, which may underlie its potential for compulsive use in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Primed Reinstatement Of 3-fma Reinforcementmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

The potent psychomotor, rewarding and reinforcing properties of 3‐fluoromethamphetamine in rodents

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Phosphorylation of MeCP2 at Ser421 contributes to neural and behavioral responses to psychostimulants in mice, whereas phosphorylation of MeCP2 in the nucleus accumbens (NAc) is mediated by D1-like DA receptors, including DA receptors D1 (DRD1) and D5 (DRD5) ( Deng et al, 2010 ). There is growing evidence that both calcium signaling and DRD1 are involved in METH-induced neurotoxicity ( Ares-Santos et al, 2012 ; Ares-Santos et al, 2013 ; Friend and Keefe, 2013 ; Andres et al, 2015 ; Sun et al, 2015 ; Nguyen et al, 2018 ), and activation of DRD1 can significantly induce neuronal damage ( Park et al, 2019 ). Therefore, DRD1-mediated phosphorylation of MeCP2 may be a critical mechanism in METH-induced neurotoxicity.…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol prevents methamphetamine-induced neurotoxicity by modulating dopamine receptor D1-mediated calcium-dependent phosphorylation of methyl-CpG-binding protein 2

et al. 2022

View full text Add to dashboard Cite

In the past decade, methamphetamine (METH) abuse has sharply increased in the United States, East Asia, and Southeast Asia. METH abuse not only leads to serious drug dependence, but also produces irreversible neurotoxicity. Currently, there are no approved pharmacotherapies for the treatment of METH use disorders. Cannabidiol (CBD), a major non-psychoactive (and non-addictive) cannabinoid from the cannabis plant, shows neuroprotective, antioxidative, and anti-inflammatory properties under METH exposure. At present, however, the mechanisms underlying these properties remain unclear, which continues to hinder research on its therapeutic potential. In the current study, computational simulations showed that CBD and METH may directly bind to the dopamine receptor D1 (DRD1) via two overlapping binding sites. Moreover, CBD may compete with METH for the PHE-313 binding site. We also found that METH robustly induced apoptosis with activation of the caspase-8/caspase-3 cascade in-vitro and in-vivo, while CBD pretreatment prevented these changes. Furthermore, METH increased the expression of DRD1, phosphorylation of Methyl-CpG-binding protein 2 (MeCP2) at serine 421 (Ser421), and level of intracellular Ca2+in-vitro and in-vivo, but these effects were blocked by CBD pretreatment. The DRD1 antagonist SCH23390 significantly prevented METH-induced apoptosis, MeCP2 phosphorylation, and Ca2+ overload in-vitro. In contrast, the DRD1 agonist SKF81297 markedly increased apoptosis, MeCP2 phosphorylation, and Ca2+ overload, which were blocked by CBD pretreatment in-vitro. These results indicate that CBD prevents METH-induced neurotoxicity by modulating DRD1-mediated phosphorylation of MeCP2 and Ca2+ signaling. This study suggests that CBD pretreatment may resist the effects of METH on DRD1 by competitive binding.

show abstract

25C-NBF, a new psychoactive substance, has addictive and neurotoxic potential in rodents

et al. 2020

View full text Add to dashboard Cite

Role of dopamine D1 receptor in 3-fluoromethamphetamine-induced neurotoxicity in mice

Cited by 11 publications

References 84 publications

The potent psychomotor, rewarding and reinforcing properties of 3‐fluoromethamphetamine in rodents

The potent psychomotor, rewarding and reinforcing properties of 3‐fluoromethamphetamine in rodents

Cannabidiol prevents methamphetamine-induced neurotoxicity by modulating dopamine receptor D1-mediated calcium-dependent phosphorylation of methyl-CpG-binding protein 2

25C-NBF, a new psychoactive substance, has addictive and neurotoxic potential in rodents

Contact Info

Product

Resources

About